Ceftolozane/Tazobactam therapy for treating nosocomial infections, associated with the XDR strains of Pseudomonas aeruginosa among patients with Acute Myeloid Leukaemia with myelotoxic agranulocytosis
Latest Information Update: 21 Jul 2020
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Nosocomial infections; Nosocomial pneumonia
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association